Table 4.
Common treatment-emergent adverse events (incidence ≥10% by preferred term).
| System Organ Class/Preferred Term | n = 40 |
|---|---|
| Any treatment-emergent adverse event, n (%) | 39 (97.5) |
| Skin and subcutaneous tissue disorders, n (%) | 33 (82.5) |
| Rash | 19 (47.5) |
| Photosensitivity reaction | 11 (27.5) |
| Maculopapular rash | 9 (22.5) |
| Alopecia | 4 (10.0) |
| Investigations, n (%) | 22 (55.0) |
| Blood creatinine phosphokinase increased | 13 (32.5) |
| Gamma-glutamyltransferase increased | 5 (12.5) |
| C-reactive protein increased | 4 (10.0) |
| General disorders and administration site conditions, n (%) | 21 (52.5) |
| Pyrexia | 11 (27.5) |
| Fatigue | 8 (20.0) |
| Oedema peripheral | 5 (12.5) |
| Infections and infestations, n (%) | 21 (52.5) |
| Upper respiratory tract infection | 8 (20.0) |
| Conjunctivitis | 6 (15.0) |
| Urinary tract infection | 4 (10.0) |
| Gastrointestinal disorders, n (%) | 20 (50.0) |
| Diarrhea | 13 (32.5) |
| Vomiting | 6 (15.0) |
| Nausea | 5 (12.5) |
| Musculoskeletal and connective tissue disorders, n (%) | 14 (35.0) |
| Arthralgia | 11 (27.5) |
| Musculoskeletal pain | 4 (10.0) |
| Myalgia | 4 (10.0) |
| Pain in extremity | 4 (10.0) |
| Eye disorders, n (%) | 12 (30.0) |
| Vision blurred | 6 (15.0) |
| Chorioretinopathy | 4 (10.0) |
| Nervous system disorders, n (%) | 12 (30.0) |
| Headache | 6 (15.0) |
| Metabolism and nutrition disorders, n (%) | 7 (17.5) |
| Decreased appetite | 4 (10.0) |
| Hypokalemia | 4 (10.0) |
| Hypertension | 5 (12.5) |